Eleven Biotherapeutics announced the appointment of Gregory D. Perry as Chief Financial and Business Officer, Daniel S. Lynch as Chairman of the company's board of directors and Jane Pritchett Henderson as a member of the board of directors. Prior to joining Eleven Biotherapeutics, Gregory D. Perry served as Interim Chief Financial Officer of InVivo Therapeutics (NVIV). Daniel S. Lynch spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer.

Jane Pritchett Henderson is Senior Vice President and Chief Business Officer at Kolltan Pharmaceuticals.